SignatureFD’s BioAtla BCAB Stock Holding History

SignatureFD’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3	Closed	-$3K	–	3141
2021 Q4	$3K	Buy	+3	New	+$3.84K	﹤0.01%	2554
2021 Q3	–	Sell	-1	Closed	-$1.95K	–	3042
2021 Q2	$1K	Buy	+1	New	+$2.26K	﹤0.01%	2683

Other funds holding BCAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SignatureFD's BCAB Position: Q1 2022 in Review

SignatureFD sold out of BioAtla (BCAB) in Q1 2022, closing a stake of 3 shares — an estimated $3K sold.

SignatureFD first reported a position in BCAB in Q2 2021 and held it in 2 quarters. The position peaked at $3K in Q4 2021. 97 funds tracked by Wall St. Rank hold BCAB as of Q1 2022.

SignatureFD reported no remaining BioAtla position as of Q1 2022 after selling out during the quarter.
SignatureFD sold 3 BioAtla shares in Q1 2022, an estimated $3K.
SignatureFD first reported a position in BioAtla in Q2 2021 and held it in 2 quarters.
SignatureFD's BioAtla position peaked at $3K in Q4 2021.
97 funds tracked by Wall St. Rank held BioAtla as of Q1 2022.

Based on SignatureFD's 13F filing for Q1 2022, filed 2 May 2022.